Publications by authors named "Jacob Udell"

Background: An initial decline in estimated glomerular filtration rate (eGFR) often leads to reluctance to continue life-saving therapies in patients with heart failure (HF).

Objectives: The goal of this study was to describe the association between initial decline in eGFR and subsequent clinical outcomes in patients randomized to placebo or finerenone.

Methods: In this prespecified analysis of FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure), we examined the association between initial decline in eGFR (≥15%) from randomization to 1 month and subsequent outcomes in patients assigned to finerenone or placebo.

View Article and Find Full Text PDF

Aims: In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2 diabetes mellitus (T2DM) in acute MI trials are sparse. The treatment effect of empagliflozin in those with and without T2DM in acute MI is unknown.

View Article and Find Full Text PDF

Objective: Event capture in clinical trials is resource-intensive, and electronic medical records (EMRs) offer a potential solution. This study develops algorithms for EMR-based death and hospitalization capture and compares them with traditional event capture methods.

Materials And Methods: We compared the effectiveness of EMR-based event capture and site-captured events adjudicated by a clinical endpoint committee in the multi-center INfluenza Vaccine to Effectively Stop cardio Thoracic Events and Decompensated heart failure (INVESTED) trial for participants from the Veterans Affairs healthcare system.

View Article and Find Full Text PDF

Purpose And Introduction: Growing evidence suggests SARS-CoV-2 infection increases the risk of long term cardiovascular, neurological, and other effects. However, post-acute health care costs following SARS-CoV-2 infection are not known.

Patients And Statistical Methods: Beginning 56 days following SARS-CoV-2 polymerase chain reaction (PCR) testing, we compared person-specific total and component health care costs (2020 CAD$) for the first year of follow-up at the mean and 99 percentiles of health care costs for matched test-positive and test-negative adults in Ontario, Canada, between January 1, 2020, and March 31, 2021.

View Article and Find Full Text PDF
Article Synopsis
  • Steroidal mineralocorticoid receptor antagonists help patients with heart failure and reduced ejection fraction, but their effectiveness in those with mildly reduced or preserved ejection fraction is unclear, indicating a need for further research on finerenone.
  • In a double-blind study, patients with heart failure (ejection fraction 40% or greater) were assigned to receive either finerenone or a placebo to assess its impact on heart failure events and cardiovascular death.
  • Results showed that finerenone led to fewer worsening heart failure events and a lower overall rate of primary outcome events compared to placebo, although it also carried a higher risk of hyperkalemia.
View Article and Find Full Text PDF

Background: In patients with type 2 diabetes mellitus (T2DM), a history of an ischemic event is associated with increased risk for cardiovascular (CV) disease. Whether patients with T2DM and a recent atherothrombotic diagnosis benefit from early intervention with a sodium-glucose co-transporter 2 inhibitor is unknown.

Methods: This study is a secondary analysis of the gliflozin Cardiovascular Event Trial in Type 2 Diabetes Mellitus Patients-emoving xcess lucose (EMPA-REG OUTCOME), which compared empagliflozin to placebo in adults with T2DM and atherosclerotic CV disease (ASCVD).

View Article and Find Full Text PDF
Article Synopsis
  • This study examined the impact of high-dose influenza vaccination on patients with adult congenital heart disease (ACHD) compared to those without ACHD, focusing on all-cause mortality and cardiopulmonary hospitalizations.
  • 272 ACHD patients were included, revealing that they were generally younger and had specific health conditions compared to the non-ACHD group of 4,988 individuals.
  • Results showed no significant difference in the primary outcomes between ACHD and non-ACHD groups, indicating that both high- and standard-dose vaccines had similar effects on health outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • SGLT2 inhibitors are drugs studied for their effectiveness in various conditions such as heart failure, type 2 diabetes, and chronic kidney disease, focusing on their impact on specific health outcomes across different patient groups.
  • This systematic review and meta-analysis included 15 large trials with over 100,000 participants and evaluated the effects of SGLT2 inhibitors compared to placebo.
  • The findings showed that SGLT2 inhibitors significantly reduced the risk of first hospitalisation for heart failure and cardiovascular death in patients across all the mentioned conditions.
View Article and Find Full Text PDF

Aims: To describe the baseline characteristics of participants in the FINEARTS-HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS-HF trial is comparing the effects of the non-steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF.

Methods And Results: Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.

View Article and Find Full Text PDF
Article Synopsis
  • Empagliflozin, a medication tested in the EMPACT-MI trial, showed promise in reducing heart failure (HF) hospitalizations but did not impact overall mortality when administered within two weeks post-acute myocardial infarction (AMI).
  • In the study of over 6,500 patients, worsening left ventricular ejection fraction (LVEF) and congestion significantly increased the risk of death and HF hospitalizations.
  • The drug effectively lowered the risk for HF hospitalizations regardless of the patients' LVEF status or congestion, and its safety profile remained consistent across different patient groups.
View Article and Find Full Text PDF
Article Synopsis
  • Empagliflozin is known to improve cardiovascular outcomes in various patient groups, but its safety and effectiveness in those who have experienced an acute myocardial infarction were previously unclear.
  • In a study involving 6522 patients at risk for heart failure after a heart attack, participants were given either empagliflozin or a placebo, with their health monitored over about 18 months.
  • The results showed that empagliflozin did not significantly reduce the risk of hospitalization for heart failure or death compared to placebo, though it did show some potential benefits regarding hospitalizations specifically for heart failure.
View Article and Find Full Text PDF
Article Synopsis
  • A secondary analysis of the INVESTED trial found that high-dose trivalent influenza vaccines didn't significantly lower mortality or hospitalizations for patients with high-risk cardiovascular disease compared to standard-dose quadrivalent vaccines.
  • The study focused on the antibody response to these vaccines and how it relates to clinical outcomes among patients who had recent heart issues.
  • Results showed that high-dose vaccines produced a stronger antibody response for various influenza strains, indicating a better immune response despite no clear impact on health outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • * In the EMPACT-MI trial, 6,522 patients were randomly assigned to receive either empagliflozin or placebo, with the results showing a significant difference in HF events after a median follow-up of 17.9 months.
  • * The study also noted that patients taking empagliflozin required fewer additional heart failure medications after discharge, indicating a broader benefit in managing heart failure risks.
View Article and Find Full Text PDF

Background: Dyslipidemia management is a cornerstone in cardiovascular disease prevention and relies heavily on patient adherence to lifestyle modifications and medications. Numerous cholesterol patient education materials are available online, but it remains unclear whether these resources are suitable for the majority of North American adults given the prevalence of low health literacy. This review aimed to (1) identify printable cholesterol patient education materials through an online search, and (2) evaluate the readability, understandability, and actionability of each resource to determine its utility in practice.

View Article and Find Full Text PDF

James et al report the results of the DAPA-MI (DAPAagliflozin in patients without diabetes mellitus with acute Myocardial Infarction) trial, which studied the efficacy and safety of early initiation of dapagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, in patients with acute myocardial infarction (MI) without type 2 diabetes (T2D) or heart failure (HF). The trial was conducted within the SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) and NICOR (National Institute for Cardiovascular Outcomes Research) registries, leveraging where possible routinely collected health data to augment screening, baseline characteristic ascertainment, and clinical follow-up.

View Article and Find Full Text PDF

Background: Primary care electronic medical record (EMR) data can be used to identify, manage, and screen hypertension cases. However, this approach relies on completeness and accessibility of documented blood pressure (BP) values. With the large switch to virtual care due to the COVID-19 pandemic, we assessed BP documentation in primary care EMRs during the pandemic, across patient and physician groups.

View Article and Find Full Text PDF

Background: Prediction of atherosclerotic cardiovascular disease (ASCVD) in primary prevention assessments exclusively with laboratory results may facilitate automated risk reporting and improve uptake of preventive therapies.

Objective: To develop and validate sex-specific prediction models for ASCVD using age and routine laboratory tests and compare their performance with that of the pooled cohort equations (PCEs).

Design: Derivation and validation of the CANHEART (Cardiovascular Health in Ambulatory Care Research Team) Lab Models.

View Article and Find Full Text PDF

Background: Canadian data suggest that patients of lower socioeconomic status with acute myocardial infarction receive less beneficial therapy and have worse clinical outcomes, raising questions regarding care disparities even in universal health care systems. We assessed the contemporary association of marginalization with clinical outcomes and health services use.

Methods: Using clinical and administrative databases in Ontario, Canada, we conducted a population-based study of patients aged ≥65 years hospitalized for their first acute myocardial infarction between April 1, 2010 and March 1, 2019.

View Article and Find Full Text PDF

Aim: We studied the association between neighbourhood material deprivation, a metric estimating inability to attain basic material needs, with outcomes and processes of care among incident heart failure patients in a universal healthcare system.

Methods And Results: In a population-based retrospective study (2007-2019), we examined the association of material deprivation with 1-year all-cause mortality, cause-specific hospitalization, and 90-day processes of care. Using cause-specific hazards regression, we quantified the relative rate of events after multiple covariate adjustment, stratifying by age ≤65 or ≥66 years.

View Article and Find Full Text PDF
Article Synopsis
  • - The study explored whether high-dose trivalent influenza vaccines provide better protection against serious heart and lung events compared to standard-dose quadrivalent vaccines in high-risk cardiovascular patients during flu season.
  • - Conducted as a secondary analysis of the INVESTED trial from 2016 to 2019, involving 3,094 patients, the research tracked weekly flu activity and its impact on health outcomes.
  • - Results indicated that increasing influenza-like illness (ILI) activity correlated with a higher risk of serious health events, but high-dose vaccines did not show a significant advantage over standard doses in preventing these issues.
View Article and Find Full Text PDF